Balchem Corporation — Q1 2016 Form 10-Q
Business context and period: Specialty performance ingredients and products company; report covers the three months ended March 31, 2016, compared with Q1 2015. Amounts are in $thousands unless noted. On February 1, 2016, Balchem acquired Albion International, adding mineral nutrition products to Human Nutrition & Health and Specialty Products.
Financial performance
| Metric | Q1 2016 | Q1 2015 | Change |
|---|---|---|---|
| Net sales | $135,141 | $144,862 | Down 6.7% |
| Gross margin | $42,824 | $43,130 | Down 0.7%; margin rose to 31.7% from 29.8% |
| Operating earnings | $19,968 | $25,038 | Down 20.2%; operating margin 14.8% vs. 17.3% |
| Net earnings | $11,886 | $15,172 | Down 21.7% |
| Diluted EPS | $0.37 | $0.48 | Down $0.11 |
| Operating cash flow | $29,323 | $26,598 | Up $2,725 |
| Capital expenditures | $10,660 | $6,368 | Up $4,292 |
Cash and cash equivalents were $39,172 at March 31, 2016, down from $84,795 at year-end, primarily reflecting the Albion acquisition. Working capital was $98,839, versus $117,172 at December 31, 2015. Gross debt was $353,750, including $65,000 drawn on a $100,000 revolving facility; $35,000 of term debt was current. The debt maturity date is May 7, 2019, and the reported interest rate was 1.93%. Balchem was in compliance with its quarterly debt covenants.
Material changes and operating drivers
- Human Nutrition & Health sales rose 5.6% to $71,555, including $7,094 from Albion; lower Powder & Flavor Systems sales partly offset the increase. Segment earnings rose 8.7% to $8,372.
- Animal Nutrition & Health sales fell 8.1% to $39,232 and segment earnings fell 23.2% to $6,535. Management cited weaker dairy economics, competition, lower feed-grade choline prices, and unfavorable product mix.
- Specialty Products sales increased 26.1% to $17,117, including $3,523 from Albion; segment earnings fell to $5,288, partly due to acquired-inventory fair-value charges.
- Industrial Products sales fell 65.2% to $7,237 and segment earnings fell to $234, primarily because of reduced shale-fracking-related demand, lower prices, and resulting manufacturing inefficiencies.
- Reported gross margin dollars edged down, but gross margin percentage improved, reflecting product mix and lower raw-material costs. Operating expenses increased to $22,856 from $18,092, including Albion expenses and acquisition/integration costs.
Cash, acquisition, outlook and risks
- Albion consideration and related payments totaled approximately $116.4 million; the purchase was funded with $65 million of revolver borrowings and existing cash. Albion contributed $10,611 in sales and a $520 net loss from February 1 through March 31. Purchase accounting remained preliminary; reported goodwill added was $57,762.
- Q1 investing cash outflow was $121,414, including $110,601 net cash paid for the acquisition. Financing cash inflow was $45,852, including the $65,000 revolver draw. Operating cash flow benefited in part from increases in accounts payable and accrued expenses.
- Management said it expects operations to generate sufficient cash to fund working capital, capital investment, and debt service, and continues to pursue acquisition candidates. The filing provides no quantified earnings or revenue guidance.
- Key exposures include floating-rate debt, foreign exchange, raw-material costs, animal-nutrition sensitivity to dairy economics, and industrial demand tied to shale activity. A 100-basis-point rate change was estimated to affect annual interest expense and cash flow by approximately $3,538.
- The filing describes environmental remediation matters and other litigation/claims; management believed these would not materially affect financial position, results, or liquidity. No material change to previously disclosed risk factors was reported. Albion was being integrated into internal controls, with inclusion in the year-end 2016 assessment expected.
Important facts for investors to verify
- Whether Albion integration, final purchase-price allocation, and expected synergies support the acquisition’s strategic and financial rationale.
- How much of sales and margin trends reflect underlying volume and pricing versus acquisitions, inventory fair-value adjustments, and acquisition costs.
- Whether weakness in Animal Nutrition & Health and Industrial Products persists, and how quickly those segments recover.
- Cash generation, working-capital movements, capital spending, and capacity to reduce debt while pursuing further acquisitions and paying dividends.
- Compliance with debt covenants and sensitivity to floating rates; also review the full annual-report risk factors and contingency disclosures.